-
Je něco špatně v tomto záznamu ?
Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis
T Reischig, P Jindra, O Hes, M Bouda, S Kormunda, V Treska
Jazyk angličtina Země Spojené státy americké
- MeSH
- analýza přežití MeSH
- antivirové látky terapeutické užití MeSH
- atrofie MeSH
- biopsie MeSH
- časové faktory MeSH
- cyklosporin terapeutické užití MeSH
- cytomegalovirové infekce epidemiologie farmakoterapie prevence a kontrola MeSH
- dospělí MeSH
- fibróza MeSH
- financování organizované MeSH
- imunosupresiva terapeutické užití MeSH
- ledvinové kanálky patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- přežívající MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- transplantace ledvin imunologie mortalita patologie škodlivé účinky MeSH
- viremie epidemiologie farmakoterapie prevence a kontrola MeSH
- virová nálož MeSH
- výběr pacientů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
BACKGROUND: Cytomegalovirus (CMV) is a risk factor for acute renal allograft rejection. The aim of this study was to determine the impact of CMV viremia on subclinical rejection (SCR) and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsy at 3 months after transplantation. METHODS: A total of 118 consecutive renal transplant recipients at risk for CMV (donor and recipient CMV seropositive) were included and followed up prospectively. Protocol biopsies with sufficient tissue were obtained in 102 patients. CMV activity was monitored using real-time polymerase chain reaction in whole blood. Three-month prophylaxis with valacyclovir or ganciclovir was given in 60 patients, whereas the remaining 42 patients were managed by preemptive therapy. Multivariate logistic stepwise regression analysis was used to estimate the effect of CMV viremia and other covariates on SCR and IF/TA. RESULTS: CMV viremia occurred in 41% of the patients with a median peak viral load of 1300 copies/mL. The incidence of SCR and IF/TA was 29% and 28%, respectively. CMV viremia was not a risk factor for SCR (OR=0.77, P=0.551); however, viremia of more than or equal to 2000 copies/mL increased the risk of IF/TA (OR=3.83, P=0.023). Biopsy-proven acute rejection (OR=3.34, P=0.009) and sirolimus-based immunosuppression (OR=6.13, P=0.008) were independent predictors of SCR. Delayed-graft function (OR=6.02, P=0.001) and donor age (OR=1.53 per 10-year increase, P=0.009) were associated with IF/TA. CONCLUSIONS: CMV viremia is not an independent risk factor for SCR. CMV viremia with viral load of more than or equal to 2000 copies/mL is associated with increased risk of IF/TA in protocol biopsy at 3 months after transplantation
Citace poskytuje Crossref.org
- 000
- 02674naa 2200625 a 4500
- 001
- bmc11006068
- 003
- CZ-PrNML
- 005
- 20250402103522.0
- 008
- 110331s2009 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1097/tp.0b013e318192ded5 $2 doi
- 035 __
- $a (PubMed)19202451
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Reischig, Tomáš, $d 1972- $7 nlk20050170377
- 245 10
- $a Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis / $c T Reischig, P Jindra, O Hes, M Bouda, S Kormunda, V Treska
- 314 __
- $a Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. reischig@fnplzen.cz
- 520 9_
- $a BACKGROUND: Cytomegalovirus (CMV) is a risk factor for acute renal allograft rejection. The aim of this study was to determine the impact of CMV viremia on subclinical rejection (SCR) and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsy at 3 months after transplantation. METHODS: A total of 118 consecutive renal transplant recipients at risk for CMV (donor and recipient CMV seropositive) were included and followed up prospectively. Protocol biopsies with sufficient tissue were obtained in 102 patients. CMV activity was monitored using real-time polymerase chain reaction in whole blood. Three-month prophylaxis with valacyclovir or ganciclovir was given in 60 patients, whereas the remaining 42 patients were managed by preemptive therapy. Multivariate logistic stepwise regression analysis was used to estimate the effect of CMV viremia and other covariates on SCR and IF/TA. RESULTS: CMV viremia occurred in 41% of the patients with a median peak viral load of 1300 copies/mL. The incidence of SCR and IF/TA was 29% and 28%, respectively. CMV viremia was not a risk factor for SCR (OR=0.77, P=0.551); however, viremia of more than or equal to 2000 copies/mL increased the risk of IF/TA (OR=3.83, P=0.023). Biopsy-proven acute rejection (OR=3.34, P=0.009) and sirolimus-based immunosuppression (OR=6.13, P=0.008) were independent predictors of SCR. Delayed-graft function (OR=6.02, P=0.001) and donor age (OR=1.53 per 10-year increase, P=0.009) were associated with IF/TA. CONCLUSIONS: CMV viremia is not an independent risk factor for SCR. CMV viremia with viral load of more than or equal to 2000 copies/mL is associated with increased risk of IF/TA in protocol biopsy at 3 months after transplantation
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antivirové látky $x terapeutické užití $7 D000998
- 650 _2
- $a atrofie $7 D001284
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a cyklosporin $x terapeutické užití $7 D016572
- 650 _2
- $a cytomegalovirové infekce $x epidemiologie $x farmakoterapie $x prevence a kontrola $7 D003586
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibróza $7 D005355
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a transplantace ledvin $x imunologie $x mortalita $x patologie $x škodlivé účinky $7 D016030
- 650 _2
- $a ledvinové kanálky $x patologie $7 D007684
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výběr pacientů $7 D018579
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a přežívající $7 D017741
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a virová nálož $7 D019562
- 650 _2
- $a viremie $x epidemiologie $x farmakoterapie $x prevence a kontrola $7 D014766
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Jindra, Pavel, $7 xx0098857 $d 1966-
- 700 1_
- $a Hes, Ondřej, $d 1968- $7 jn20001103502
- 700 1_
- $a Bouda, Mirko $7 xx0330644
- 700 1_
- $a Kormunda, Stanislav $7 xx0103970
- 700 1_
- $a Třeška, Vladislav, $d 1957- $7 jn20000402436
- 773 0_
- $t Transplantation $w MED00010695 $g Roč. 87, č. 3 (2009), s. 436-444
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110414095825 $b ABA008
- 991 __
- $a 20250402103519 $b ABA008
- 999 __
- $a ok $b bmc $g 833697 $s 698157
- BAS __
- $a 3
- BMC __
- $a 2009 $b 87 $c 3 $d 436-444 $m Transplantation $n Transplantation $x MED00010695
- LZP __
- $a 2011-1B09/dkme